This is the authors' abstract. We don't add key points for this paper.
Supramolecular cancer nanotheranostics have shown promising potentials in early-stage diagnosis and personal therapy. Herein, we summarize the progress of supramolecular cancer nanotheranostics and provide guidance for designing new targeted supramolecular theranostic agents.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2021) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: